Biotech company Intellia Therapeutics is struggling after its promising gene-editing treatment was linked to liver toxicity. The risk of death from liver injury makes the treatment’s benefits less clear, especially since recently approved options for other diseases are becoming more effective and convenient. This challenges Intellia’s lead programs focused on transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE), which now face increased competition.
Source: https://www.statnews.com/2025/10/27/intellia-therapeutics-crispr-impact